CRAD B logo

C-Rad AB (publ) Stock Price

OM:CRAD B Community·SEK 1.3b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

CRAD B Share Price Performance

SEK 37.40
3.00 (8.72%)
SEK 36.00
Fair Value
SEK 37.40
3.00 (8.72%)
3.9% overvalued intrinsic discount
SEK 36.00
Fair Value
Price SEK 37.40
AnalystConsensusTarget SEK 36.00

CRAD B Community Narratives

·
Fair Value SEK 36 3.9% overvalued intrinsic discount

Aging Population And Healthcare Digitization Will Expand Radiotherapy Demand

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
SEK 36
3.9% overvalued intrinsic discount
Revenue
10.17% p.a.
Profit Margin
18.74%
Future PE
13.46x
Price in 2029
SEK 41.89

Trending Discussion

No trending discussion available.

Updated Narratives

CRAD B logo

CRAD B: Partnership Integration And Revised Assumptions Will Support A Balanced Outlook

Fair Value: SEK 36 3.9% overvalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards

C-Rad AB (publ) Key Details

SEK 427.8m

Revenue

SEK 111.6m

Cost of Revenue

SEK 316.2m

Gross Profit

SEK 286.5m

Other Expenses

SEK 29.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 17, 2026
0.88
73.92%
6.96%
0%
View Full Analysis

About CRAD B

Founded
2004
Employees
113
CEO
Tomas Blomquist
WebsiteView website
c-rad.com

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.

Recent CRAD B News & Updates

Narrative Update Jun 26

CRAD B: Partnership Integration And Revised Assumptions Will Support A Balanced Outlook

Analysts have lifted their C-Rad price target from SEK 30 to SEK 36, citing updated assumptions for revenue growth of 10.17%, profit margins of 18.74%, a P/E of 13.46x, and a slightly lower discount rate of 5.66% in their valuation work. What's in the News for C-Rad C-Rad AB and SeeTreat Pty Ltd formed a partnership combining C-Rad’s Catalyst# HD platform for patient setup and real-time motion monitoring with SeeTreat’s ART.1 software for automated adaptive plan decision support in radiotherapy sessions.

Recent updates

No updates